NCT00306631View on ClinicalTrials.gov

A Study to Determine the Antitumor Activity and Evaluate the Safety of MKC-1

PHASE2CompletedINTERVENTIONAL
Enrollment

65

Participants

Timeline

Start Date

January 31, 2006

Primary Completion Date

April 30, 2008

Study Completion Date

November 30, 2008

Conditions
Breast Cancer
Interventions
DRUG

MKC-1

Oral capsules, 30 mg and 100 mg capsule strengths; administered twice daily for 14 days in a 28 day cycle

Trial Locations (1)

Unknown

IUPUI, Indianapolis

Sponsors
All Listed Sponsors
lead

CASI Pharmaceuticals, Inc.

INDUSTRY